Nebenwirkungen · Imfinzi
IMFINZI 50 mg/ml concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 15–16
HOS-141795 · Präparat HOS-098696
15 The safety of IMFINZI in combination with chemotherapy is based on pooled data in 2 244 patients from 6 studies (TOPAZ-1, CASPIAN, DUO-E, AEGEAN, NIAGARA and MATTERHORN). The most common (> 10%) adverse reactions were neutropenia (44.6%), nausea (42.4%), fatigue (41.2%), anaemia (37.4%), diarrhoea (27.5%), constipation (26.7%), decreased appetite (24.0%), alopecia (22.0%), neuropathy peripheral (21.6%), thrombocytopenia (19.7%), rash (19.7%), vomiting (18.8%), abdominal pain (17.9%), pyrexia (15.2%), leukopenia (14.9%), pruritus (12.5%), hypothyroidism (11.1%), arthralgia (10.9%), cough/productive cough (10.8%), and aspartate aminotransferase increased/alanine aminotransferase increased (10.5%). The most common (> 2%) NCI CTCAE Grade ≥ 3 adverse reactions were neutropenia (28.5%), anaemia (11.9%), thrombocytopenia (5.6%), leukopenia (4.9%), fatigue (3.3%), pneumonia (2.5%), febrile neutropenia (2.4%), and diarrhoea (2.3%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T16:10:00Z · SHA-256 2aea150cfee5fbe605596424a5c30efdb4cdb269005b61f75a72ebb78beb905f · Passage e62413010b4839de07d6db1ffa880cefd3021a286653027afefaf4173de5c453 · Zeichen 2121–3061 im Abschnitt